NO331277B1 - Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit - Google Patents

Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit

Info

Publication number
NO331277B1
NO331277B1 NO20034452A NO20034452A NO331277B1 NO 331277 B1 NO331277 B1 NO 331277B1 NO 20034452 A NO20034452 A NO 20034452A NO 20034452 A NO20034452 A NO 20034452A NO 331277 B1 NO331277 B1 NO 331277B1
Authority
NO
Norway
Prior art keywords
polypeptide
nucleic acid
antibody
methods
treatment
Prior art date
Application number
NO20034452A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034452L (no
NO20034452D0 (no
Inventor
Thierry Leveillard
Saddek Mohand-Said
Jose Alain Sahel
David Hicks
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20034452D0 publication Critical patent/NO20034452D0/no
Publication of NO20034452L publication Critical patent/NO20034452L/no
Publication of NO331277B1 publication Critical patent/NO331277B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20034452A 2001-04-06 2003-10-03 Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit NO331277B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (3)

Publication Number Publication Date
NO20034452D0 NO20034452D0 (no) 2003-10-03
NO20034452L NO20034452L (no) 2003-12-04
NO331277B1 true NO331277B1 (no) 2011-11-14

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034452A NO331277B1 (no) 2001-04-06 2003-10-03 Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit

Country Status (22)

Country Link
US (6) US7795387B2 (ko)
EP (1) EP1379657B1 (ko)
JP (2) JP4370428B2 (ko)
KR (1) KR100913258B1 (ko)
CN (1) CN1529753B (ko)
AU (1) AU2002312794B8 (ko)
BR (1) BRPI0208870B8 (ko)
CA (1) CA2443345C (ko)
CZ (1) CZ305800B6 (ko)
EC (1) ECSP024345A (ko)
ES (1) ES2597835T3 (ko)
FR (1) FR2823221B1 (ko)
HU (1) HU226307B1 (ko)
IL (3) IL158013A0 (ko)
MX (1) MXPA03009114A (ko)
NO (1) NO331277B1 (ko)
NZ (1) NZ528376A (ko)
PL (1) PL213658B1 (ko)
RU (1) RU2384586C2 (ko)
SK (1) SK288465B6 (ko)
WO (1) WO2002081513A2 (ko)
ZA (1) ZA200307403B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
ATE490307T1 (de) 2003-05-21 2010-12-15 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
EP2281047B1 (en) * 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
ES2548980T3 (es) 2008-09-10 2015-10-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Factor de viabilidad neuronal y uso del mismo
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
AU2012321102C1 (en) * 2011-10-27 2016-11-10 Pharma Cinq, Llc Vectors encoding rod-derived cone viability factor
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
EP2909232B1 (en) 2012-10-17 2020-03-11 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd)
DK3027646T3 (en) 2013-07-31 2018-09-24 Novartis Ag New selection vectors and methods for selecting eukaryotic host cells
WO2016185242A1 (en) * 2015-05-21 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of neuronal viability factors and uses thereof
US10857240B2 (en) 2016-01-05 2020-12-08 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
CA3025977A1 (en) 2016-10-11 2018-04-19 Wellstat Ophthalmics Corporation Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
EP4268895A3 (en) * 2019-12-09 2024-01-10 Chigenovo Co., Ltd. Uses of cyp4v2 and rdcvf in preparation of drugs
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
ES2548980T3 (es) 2008-09-10 2015-10-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Factor de viabilidad neuronal y uso del mismo

Also Published As

Publication number Publication date
CN1529753B (zh) 2013-06-12
EP1379657A2 (en) 2004-01-14
JP2009232843A (ja) 2009-10-15
SK288465B6 (sk) 2017-06-02
NZ528376A (en) 2005-09-30
BRPI0208870B8 (pt) 2021-05-25
CN1529753A (zh) 2004-09-15
US20090062188A1 (en) 2009-03-05
IL158013A (en) 2010-12-30
FR2823221B1 (fr) 2004-04-02
HU226307B1 (en) 2008-08-28
BRPI0208870B1 (pt) 2016-01-12
MXPA03009114A (es) 2004-11-22
NO20034452L (no) 2003-12-04
US20120108523A1 (en) 2012-05-03
AU2002312794B8 (en) 2006-01-12
JP4571695B2 (ja) 2010-10-27
BR0208870A (pt) 2004-04-27
CA2443345A1 (en) 2002-10-17
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06
AU2002312794B2 (en) 2005-12-01
US8394756B2 (en) 2013-03-12
US8957043B2 (en) 2015-02-17
WO2002081513A3 (en) 2003-05-01
ECSP024345A (es) 2004-06-28
US20040204350A1 (en) 2004-10-14
JP4370428B2 (ja) 2009-11-25
US8114849B2 (en) 2012-02-14
NO20034452D0 (no) 2003-10-03
IL158013A0 (en) 2004-03-28
WO2002081513A2 (en) 2002-10-17
KR100913258B1 (ko) 2009-08-21
US7795387B2 (en) 2010-09-14
ZA200307403B (en) 2004-04-21
EP1379657B1 (en) 2016-08-17
HUP0303730A2 (en) 2006-02-28
SK12232003A3 (sk) 2004-03-02
US8518695B2 (en) 2013-08-27
US20130287738A1 (en) 2013-10-31
IL199316A (en) 2011-01-31
ES2597835T3 (es) 2017-01-23
CA2443345C (en) 2012-12-04
JP2005502319A (ja) 2005-01-27
US20120108657A1 (en) 2012-05-03
FR2823221A1 (fr) 2002-10-11
CZ305800B6 (cs) 2016-03-23
CZ20032706A3 (cs) 2003-12-17
PL364681A1 (en) 2004-12-13
KR20030094317A (ko) 2003-12-11
PL213658B1 (pl) 2013-04-30
RU2003130638A (ru) 2005-04-20
US20080004231A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
NO331277B1 (no) Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2003025121A3 (en) Igf-binding protein-derived peptide or small molecule
JP2006506942A5 (ko)
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2005113586A3 (en) Disease-associated proteins
WO2007030708A3 (en) Antimicrobial adzymes and uses thereof
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2149051A2 (de) Verfahren und immunabsorbentien zur spezifischen detektion und absorption zöliakie- und dermatitis herpetiformis assoziierter antikörper
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003059248A3 (en) Pigment epithelium derived factor from human plasma and methods of use thereof
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
WO2002026985A3 (en) G-protein coupled recptors

Legal Events

Date Code Title Description
MK1K Patent expired